IP501, produced by Interneuron, was a compound related to lecithin, a phospholipid found in cell membranes.
It was an anti-fibrotic, taken orally. Scientists hoped it would be beneficial to people with liver cirrhosis
resulting from chronic HCV infection. A phase III clinical trial involving 800 patients was underway in the US to
determine its effectiveness of IP-501 with hepatitis C-related cirrhosis The company is now called Indevus, and IP501 is no longer included in its pipeline (
).
